Tvardi Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-23.65	-29.4	-17.35	-20.54
Depreciation & Amortization	0.1	0.1	0.1	0.09
Loss (Gain) From Sale of Investments	-0.17	-	-0.19	-0.36
Stock-Based Compensation	1.13	0.32	0.31	0.25
Other Operating Activities	-5.11	2.04	0.05	0.03
Change in Accounts Payable	5.53	5.57	-1.01	2.2
Change in Other Net Operating Assets	-0.47	3.07	-2.95	0.47
Operating Cash Flow	-22.65	-18.31	-21.04	-17.87
Capital Expenditures	-	-	-	-0.05
Investment in Securities	-15.08	-	22.47	-21.95
Investing Cash Flow	-15.08	-	22.47	-22
Long-Term Debt Issued	-	28.3	-	-
Net Debt Issued (Repaid)	28.3	28.3	-	-
Issuance of Common Stock	0.53	0.01	0	0
Other Financing Activities	20.88	-1.3	-	-
Financing Cash Flow	49.71	27	0	0
Net Cash Flow	11.98	8.7	1.43	-39.86
Free Cash Flow	-22.65	-18.31	-21.04	-17.92
Free Cash Flow Per Share	-2.38	-2.86	-3.30	-2.81
Levered Free Cash Flow	-12.51	-6.91	-15.13	-
Unlevered Free Cash Flow	-12.51	-6.91	-15.13	-
Change in Working Capital	5.06	8.64	-3.96	2.67

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q